Under the terms of the agreement, Micreos will give L'Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only unwanted bacteria in the skin flora, according to Micreos.
For 15 years, L'Oréal's Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome. "The agreement with Micreos opens up a very promising field in high-tech cosmetics," Laurent Attal, executive vice-president research and innovation of L'Oréal, said in a statement.
"We expect this partnership to be ground-breaking. L'Oréal has been a leader in skincare for decades. Micreos is at the forefront of targeted bacterial biotechnology. We pair our strengths and millions stand to benefit,” noted Micreos CEO Mark Offerhaus.
Micreos' pharma development program includes endolysins that all target Staphylococcus bacteria, which cause or aggravate a broad range of health issues, including skin condition.
You can learn more about new developments in the skin microbiome in Happi’s November 2020 issue, due out online next week.